Comparative evaluation of efficacy of Trayodashang Guggul versus Rasona Pinda as an adjuvant with Katibasti in the management of Grudhrasi (Sciatica): A randomized controlled trial.

Q2 Pharmacology, Toxicology and Pharmaceutics

F1000Research Pub Date : 2024-08-12 eCollection Date: 2024-01-01 DOI:10.12688/f1000research.139568.3

Mayank Rai, Sadhana Misar, Reeya Gamne

{"title":"Comparative evaluation of efficacy of Trayodashang Guggul versus Rasona Pinda as an adjuvant with Katibasti in the management of Grudhrasi (Sciatica): A randomized controlled trial.","authors":"Mayank Rai, Sadhana Misar, Reeya Gamne","doi":"10.12688/f1000research.139568.3","DOIUrl":null,"url":null,"abstract":"Background: In ayurveda, sciatica can be correlated to ' Grudhrasi' under Vata Nanatmaja-Vyadhi (neurological disorders caused by Vata, one of the bodily humour). In this mainly bodily humours vata and kapha are vitiating producing symptoms like piercing pain, stiffness, twitching, numbness and pain radiating from lumbosacral region to lower limb up to the foot. Therapeutic plan includes stabilizing and bringing back the vitiated vata and kapha humours to equilibrium. The prevalence of sciatica varies considerably ranging from 3.8% in the working population to 7.9% in the nonworking population.Aim: Comparative evaluation of efficacy of Rasonapinda and Trayodashang guggul as an adjuvant to katibasti (oil pooling therapy) in the management of Grudhrasi (Sciatica).Objectives: To assess the efficacy of Rasonapinda as an adjuvant to katibasti in subjective and objective parameters of Grudhrasi (Sciatica). To assess the efficacy of Trayodashang guggul as an adjuvant to katibasti in subjective and objective parameters of Grudhrasi (Sciatica). To compare the efficacy of Rasonapinda and Trayodashang guggul as an adjuvant to katibasti in subjective and objective parameters. Standardisation of Rasonapinda (modified formvati).Methods: In this study, a total of 60 patients will be enrolled and divided equally into two groups. In group A, Trayodashang Guggul 500 mg twice a day after meal with warm water for 30 days adjuvant with katibasti for the initial 7 days will be given. In group B, Rasonapinda 500 mg twice a day after meal with warm water adjuvant with katibasti for the initial 7 days will be given for 30 days.Result: The result will be assessed on baseline of subjective and objective parameters and data will be compared after treatment.Conclusions: It will be based on observations and results obtained.Trial registration: CTRI No. - CTRI/2022/12/048534 Dated - 27/12/2022.","PeriodicalId":12260,"journal":{"name":"F1000Research","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11487230/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"F1000Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.12688/f1000research.139568.3","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}

引用次数: 0

Abstract

Background: In ayurveda, sciatica can be correlated to ' Grudhrasi' under Vata Nanatmaja-Vyadhi (neurological disorders caused by Vata, one of the bodily humour). In this mainly bodily humours vata and kapha are vitiating producing symptoms like piercing pain, stiffness, twitching, numbness and pain radiating from lumbosacral region to lower limb up to the foot. Therapeutic plan includes stabilizing and bringing back the vitiated vata and kapha humours to equilibrium. The prevalence of sciatica varies considerably ranging from 3.8% in the working population to 7.9% in the nonworking population.

Aim: Comparative evaluation of efficacy of Rasonapinda and Trayodashang guggul as an adjuvant to katibasti (oil pooling therapy) in the management of Grudhrasi (Sciatica).

Objectives: To assess the efficacy of Rasonapinda as an adjuvant to katibasti in subjective and objective parameters of Grudhrasi (Sciatica). To assess the efficacy of Trayodashang guggul as an adjuvant to katibasti in subjective and objective parameters of Grudhrasi (Sciatica). To compare the efficacy of Rasonapinda and Trayodashang guggul as an adjuvant to katibasti in subjective and objective parameters. Standardisation of Rasonapinda (modified formvati).

Methods: In this study, a total of 60 patients will be enrolled and divided equally into two groups. In group A, Trayodashang Guggul 500 mg twice a day after meal with warm water for 30 days adjuvant with katibasti for the initial 7 days will be given. In group B, Rasonapinda 500 mg twice a day after meal with warm water adjuvant with katibasti for the initial 7 days will be given for 30 days.

Result: The result will be assessed on baseline of subjective and objective parameters and data will be compared after treatment.

Conclusions: It will be based on observations and results obtained.

Trial registration: CTRI No. - CTRI/2022/12/048534 Dated - 27/12/2022.

查看原文本刊更多论文

Trayodashang Guggul 与 Rasona Pinda 作为 Katibasti 的辅助药物治疗坐骨神经痛的疗效比较评估：随机对照试验。

背景：在阿育吠陀中，坐骨神经痛与 Vata Nanatmaja-Vyadhi 下的 "Grudhrasi"（由身体湿气之一的 Vata 引起的神经系统疾病）相关。在这种情况下，主要是身体湿气 Vata 和 Kapha 从腰骶部向下肢直至足部放射，产生刺痛、僵硬、抽搐、麻木和疼痛等症状。治疗方案包括稳定和恢复受损的 Vata 和 Kapha 体液的平衡。坐骨神经痛的发病率差异很大，从工作人群的 3.8%到非工作人群的 7.9%不等。目的：比较评估 Rasonapinda 和 Trayodashang guggul 作为 katibasti（油池疗法）辅助剂治疗坐骨神经痛的疗效：评估 Rasonapinda 作为 Katibasti 的辅助药物对坐骨神经痛（Grudhrasi）主观和客观参数的疗效。评估 Trayodashang guggul 作为 katibasti 的辅助剂对坐骨神经痛主观和客观参数的疗效。比较 Rasonapinda 和 Trayodashang guggul 作为 Katibasti 佐剂在主观和客观参数方面的疗效。对 Rasonapinda（改良配方）进行标准化：本研究将招募 60 名患者，平均分为两组。在 A 组中，给予 Trayodashang Guggul 500 毫克，每天两次，饭后用温水送服，连续 30 天，最初 7 天与 Katibasti 同时服用。B 组为 Rasonapinda 500 毫克，每天两次，饭后用温水送服，最初 7 天与卡替巴斯提辅助治疗，共 30 天：结果：将对主观和客观参数的基线进行评估，并对治疗后的数据进行比较：结论：将根据观察结果得出：CTRI号 - CTRI/2022/12/048534 日期 - 2022年12月27日。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

F1000Research Pharmacology, Toxicology and Pharmaceutics-Pharmacology, Toxicology and Pharmaceutics (all)

CiteScore

5.00

自引率

0.00%

发文量

1646

审稿时长

1 weeks

期刊介绍： F1000Research publishes articles and other research outputs reporting basic scientific, scholarly, translational and clinical research across the physical and life sciences, engineering, medicine, social sciences and humanities. F1000Research is a scholarly publication platform set up for the scientific, scholarly and medical research community; each article has at least one author who is a qualified researcher, scholar or clinician actively working in their speciality and who has made a key contribution to the article. Articles must be original (not duplications). All research is suitable irrespective of the perceived level of interest or novelty; we welcome confirmatory and negative results, as well as null studies. F1000Research publishes different type of research, including clinical trials, systematic reviews, software tools, method articles, and many others. Reviews and Opinion articles providing a balanced and comprehensive overview of the latest discoveries in a particular field, or presenting a personal perspective on recent developments, are also welcome. See the full list of article types we accept for more information.